查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1518241

2024 年雙胍類世界市場報告

Biguanides Global Market Report 2024
出版日期: | 出版商: The Business Research Company | 英文 175 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

預計未來幾年雙胍類藥物的市場規模將穩定成長。到2028年，這一數字將以3.8%的年複合成長率（CAGR）成長至57.6億美元。預測期內的預期成長將受到聯合治療的增加、藥物輸送技術的進步、研發投資的增加、醫療保健支出的擴大以及卵巢症候群治療的擴大等因素的推動。這段時期的主要趨勢包括對緩釋性開發的更多關注、對聯合治療的偏好增加、在腫瘤學中的廣泛使用以及療效和安全性的提高，其中包括新的和改進的雙胍的出現。

糖尿病患者數量的增加預計將在可預見的未來推動雙胍市場的擴張。糖尿病是一種以胰島素分泌不足導致血糖值升高為特徵的慢性代謝性疾病，由於生活方式的改變、人口老化、遺傳因素、診斷方法的改進以及環境影響等多種因素，其發病率呈上升趨勢。雙胍類藥物，例如Metformin，可以透過提高胰島素敏感性、減少肝臟中的葡萄糖生成以及降低 2 型糖尿病患者的血糖值幫助控制糖尿病。例如，根據英國政府機構健康改善與差異辦公室的數據，從 2022 年 3 月到 2023 年 3 月，接受全部八種建議的 1 型和 2 型糖尿病護理流程的人數顯著增加。此外，實現 HbA1c 目標的人數比例達到 37.9% 的歷史新高。因此，糖尿病盛行率的增加正在推動雙胍類藥物市場的成長。

雙胍類市場的領先公司專注於開發先進的解決方案，例如緩釋性製劑，以提高患者的依從性、提高治療效果並最大限度地減少副作用。緩釋性雙胍緩慢釋放其活性成分，有助於糖尿病患者維持恆定的血液水平，改善血糖控制並提高治療順從性。例如，2023年8月，印度生物技術公司Dr. Reddy's Laboratories推出了學名藥藥KOMBIGLYZE XR，由沙格列汀和鹽酸Metformin緩釋性獲得美國食品藥物管理局（USFDA）核准。該藥物是 DPP-4 抑制劑沙格列汀和Metformin二甲雙胍的組合藥物藥物，與飲食和運動療法合併使用可改善第 2 型糖尿病成年患者的血糖控制。緩釋性製劑可提高病患的用藥依從性和療效。

目錄

第1章執行摘要

第2章 市場特點

第3章 市場趨勢與策略

第4章宏觀經濟情景

  • 高通膨對市場的影響
  • 烏克蘭與俄羅斯戰爭對市場的影響
  • COVID-19 對市場的影響

第5章世界市場規模與成長

  • 全球雙胍類藥物市場：促進因素與限制因素
    • 市場促進因素
    • 市場限制因素
  • 全球雙胍市場表現：規模與成長，2018-2023
  • 全球雙胍市場預測：規模與成長，2023-2028，2033F

第6章 市場細分

  • 全球雙胍市場：按類型分類的表現和預測，2018-2023、2023-2028F、2033F
  • Metformin
  • 苯乙雙胍
  • 其他類型
  • 全球雙胍市場：按劑型分類的表現與預測，2018-2023、2023-2028F、2033F
  • 藥片
  • 口服液
  • 全球雙胍類市場：依配方分類的績效與預測，2018-2023、2023-2028F、2033F
  • 即時發布
  • 緩釋
  • 全球雙胍市場：按分銷管道分類的表現和預測，2018-2023、2023-2028F、2033F
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第 7 章 區域/國家分析

  • 全球雙胍市場：按地區分類的表現與預測，2018-2023、2023-2028F、2033F
  • 全球雙胍市場：按國家分類的績效和預測，2018-2023、2023-2028F、2033F

第8章亞太市場

第9章 中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章 德國市場

第18章 法國市場

第19章 義大利市場

第20章 西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章加拿大市場

第26章 南美洲市場

第27章 巴西市場

第28章 中東市場

第29章 非洲市場

第30章 競爭格局及公司概況

  • 雙胍市場：競爭格局
  • 雙胍市場：公司簡介
    • Cardinal Health Inc.
    • Pfizer Inc.
    • Merck And Co Inc
    • Bayer AG
    • Sanofi-Aventis LLC

第31章 其他大型創新企業

  • AstraZeneca plc
  • Novartis AG
  • GlaxoSmithKline plc
  • Takeda Pharmaceuticals Company Limited
  • Novo Nordisk A/S
  • Viatris Inc.
  • Daiichi Sankyo Company Limited
  • Wanbury Ltd
  • Boehringer Ingelheim International GmbH
  • Intas Pharmaceuticals Ltd.
  • Aurobindo Pharma Ltd.
  • Cipla Ltd
  • Shionogi & Co Ltd
  • Dr. Reddy's Laboratories
  • Lupin Limited

第32章競爭基準化分析

第 33 章. 競爭對手儀表板

第34章 重大併購

第35章前瞻性與潛力分析

第36章附錄

簡介目錄
Product Code: r18286

Biguanides comprise a class of medications primarily employed in the treatment of type 2 diabetes. They aid in lowering blood sugar levels by reducing the liver's production of sugar and enhancing the body's responsiveness to insulin. Additionally, these medications find utility in treating polycystic ovary syndrome (PCOS) and other metabolic disorders.

The primary types of biguanides include metformin, phenformin, and others. Metformin stands out as a widely utilized biguanide medication for type 2 diabetes management, effectively lowering blood sugar levels. Available in various dosage forms such as tablets and oral solutions, metformin is offered in different formulations including immediate-release and extended-release variants. These medications are distributed through a variety of channels including hospital pharmacies, retail pharmacies, and online platforms.

The biguanides market research report is one of a series of new reports from The Business Research Company that provides biguanides market statistics, including biguanides industry global market size, regional shares, competitors with a biguanides market share, detailed biguanides market segments, market trends and opportunities, and any further data you may need to thrive in the biguanides industry. This biguanides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biguanides market size has grown steadily in recent years. It will grow from $4.79 billion in 2023 to $4.96 billion in 2024 at a compound annual growth rate (CAGR) of 3.6%. The growth observed in the historical period can be attributed to several factors, including an increase in demand for oral hypoglycemic drugs, the growth of the geriatric population, rising obesity rates, and heightened awareness about diabetes management.

The biguanides market size is expected to see steady growth in the next few years. It will grow to $5.76 billion in 2028 at a compound annual growth rate (CAGR) of 3.8%. The anticipated growth in the forecast period is expected to be fueled by factors such as the increasing adoption of combination therapies, advancements in drug delivery technologies, rising investment in research and development, expanding healthcare expenditure, and broadening applications in the treatment of polycystic ovary syndrome. Significant trends projected for this period include a heightened focus on developing extended-release formulations, a growing preference for fixed-dose combination therapies, expanding applications in oncology, and the emergence of novel biguanides with improved efficacy and safety profiles.

The increase in diabetes cases is anticipated to drive the expansion of the biguanides market in the foreseeable future. Diabetes, a chronic metabolic disorder characterized by elevated blood sugar levels due to insufficient insulin production, is on the rise due to various factors such as lifestyle shifts, population aging, genetic factors, improved diagnostic methods, and environmental influences. Biguanides such as metformin help manage diabetes by enhancing insulin sensitivity, reducing liver glucose production, and lowering blood sugar levels in individuals with type 2 diabetes. For example, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals receiving all eight recommended care processes for type 1 and type 2 diabetes increased significantly. Additionally, the percentage of individuals achieving target HbA1c levels reached a record high of 37.9%. Therefore, the increasing prevalence of diabetes is propelling the growth of the biguanides market.

Leading companies in the biguanides market are concentrating on developing advanced solutions such as extended-release formulations to enhance patient compliance, improve therapeutic effectiveness, and minimize side effects. Extended-release biguanides slowly release their active ingredients, ensuring consistent blood levels and better glycemic control for diabetes patients, thereby enhancing treatment adherence. For instance, in August 2023, Dr. Reddy's Laboratories, an India-based biotechnology company, introduced saxagliptin and metformin hydrochloride extended-release drugs, a generic version of KOMBIGLYZE XR approved by the US Food and Drug Administration (USFDA). This combination medication, consisting of saxagliptin, a DPP-4 inhibitor, and metformin, a biguanide, aims to improve glycemic control in adults with type 2 diabetes mellitus when used in conjunction with diet and exercise. The extended-release formulation enhances patient adherence and efficacy.

In August 2023, Lupin, an India-based biopharmaceutical company, acquired diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim for an undisclosed sum. This acquisition enables Lupin to expand its product portfolio and strengthen its position in the anti-diabetes segment, ensuring broader access to medication for patients. Boehringer Ingelheim, a Germany-based biopharmaceutical company, is renowned for its research, development, and production of therapies for both human and veterinary medicine.

Major companies operating in the biguanides market are Cardinal Health Inc., Pfizer Inc., Merck And Co Inc, Bayer AG, Sanofi-Aventis LLC, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceuticals Company Limited, Novo Nordisk A/S, Viatris Inc., Daiichi Sankyo Company Limited, Wanbury Ltd, Boehringer Ingelheim International GmbH, Intas Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Cipla Ltd, Shionogi & Co Ltd, Dr. Reddy's Laboratories, Lupin Limited, Zydus Lifesciences Limited, Apotex Inc, Torrent Pharmaceuticals Limited, Panacea Biotech Ltd., Auro Laboratories Limited

Asia-Pacific was the largest region in the biguanides market in 2023. Middle East And Africa is expected to be the fastest-growing region in the forecast period. The regions covered in the biguanides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the biguanides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The biguanides market consists of sales of Chlorhexidine, Polyhexanide, Proguanil, and Buformin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biguanides Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biguanides market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biguanides ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biguanides market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Metformin; Phenformin; Other Types
  • 2) By Dosage Form: Tablets; Oral Solutions
  • 3) By Formulation: Immediate Release; Extended Release
  • 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Companies Mentioned: Cardinal Health Inc.; Pfizer Inc.; Merck And Co Inc; Bayer AG; Sanofi-Aventis LLC
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biguanides Market Characteristics

3. Biguanides Market Trends And Strategies

4. Biguanides Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Biguanides Market Size and Growth

  • 5.1. Global Biguanides Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Biguanides Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Biguanides Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Biguanides Market Segmentation

  • 6.1. Global Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Metformin
  • Phenformin
  • Other Types
  • 6.2. Global Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Tablets
  • Oral Solutions
  • 6.3. Global Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Immediate Release
  • Extended Release
  • 6.4. Global Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

7. Biguanides Market Regional And Country Analysis

  • 7.1. Global Biguanides Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Biguanides Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Biguanides Market

  • 8.1. Asia-Pacific Biguanides Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Biguanides Market

  • 9.1. China Biguanides Market Overview
  • 9.2. China Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Biguanides Market

  • 10.1. India Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Biguanides Market

  • 11.1. Japan Biguanides Market Overview
  • 11.2. Japan Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Biguanides Market

  • 12.1. Australia Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Biguanides Market

  • 13.1. Indonesia Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Biguanides Market

  • 14.1. South Korea Biguanides Market Overview
  • 14.2. South Korea Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Biguanides Market

  • 15.1. Western Europe Biguanides Market Overview
  • 15.2. Western Europe Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Biguanides Market

  • 16.1. UK Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Biguanides Market

  • 17.1. Germany Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Biguanides Market

  • 18.1. France Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Biguanides Market

  • 19.1. Italy Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Biguanides Market

  • 20.1. Spain Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Biguanides Market

  • 21.1. Eastern Europe Biguanides Market Overview
  • 21.2. Eastern Europe Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Biguanides Market

  • 22.1. Russia Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Biguanides Market

  • 23.1. North America Biguanides Market Overview
  • 23.2. North America Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Biguanides Market

  • 24.1. USA Biguanides Market Overview
  • 24.2. USA Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Biguanides Market

  • 25.1. Canada Biguanides Market Overview
  • 25.2. Canada Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Biguanides Market

  • 26.1. South America Biguanides Market Overview
  • 26.2. South America Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Biguanides Market

  • 27.1. Brazil Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Biguanides Market

  • 28.1. Middle East Biguanides Market Overview
  • 28.2. Middle East Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Biguanides Market

  • 29.1. Africa Biguanides Market Overview
  • 29.2. Africa Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Biguanides Market Competitive Landscape And Company Profiles

  • 30.1. Biguanides Market Competitive Landscape
  • 30.2. Biguanides Market Company Profiles
    • 30.2.1. Cardinal Health Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Pfizer Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck And Co Inc
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Bayer AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Sanofi-Aventis LLC
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Biguanides Market Other Major And Innovative Companies

  • 31.1. AstraZeneca plc
  • 31.2. Novartis AG
  • 31.3. GlaxoSmithKline plc
  • 31.4. Takeda Pharmaceuticals Company Limited
  • 31.5. Novo Nordisk A/S
  • 31.6. Viatris Inc.
  • 31.7. Daiichi Sankyo Company Limited
  • 31.8. Wanbury Ltd
  • 31.9. Boehringer Ingelheim International GmbH
  • 31.10. Intas Pharmaceuticals Ltd.
  • 31.11. Aurobindo Pharma Ltd.
  • 31.12. Cipla Ltd
  • 31.13. Shionogi & Co Ltd
  • 31.14. Dr. Reddy's Laboratories
  • 31.15. Lupin Limited

32. Global Biguanides Market Competitive Benchmarking

33. Global Biguanides Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Biguanides Market

35. Biguanides Market Future Outlook and Potential Analysis

  • 35.1 Biguanides Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Biguanides Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Biguanides Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer